{"id":"raloxifene-hci-and-alendronate-na","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hot flashes"},{"rate":"5-10","effect":"Leg cramps"},{"rate":"5-15","effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":"5-10","effect":"Musculoskeletal pain"},{"rate":"1-3","effect":"Venous thromboembolism (raloxifene component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raloxifene acts as a selective estrogen receptor modulator (SERM) that mimics estrogen effects on bone tissue, reducing bone turnover and resorption. Alendronate is a bisphosphonate that binds to hydroxyapatite in bone and inhibits osteoclast function, further suppressing bone resorption. Together, these complementary mechanisms work synergistically to increase bone mineral density and reduce fracture risk in postmenopausal women.","oneSentence":"This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:48.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postmenopausal osteoporosis prevention and treatment"}]},"trialDetails":[{"nctId":"NCT00035971","phase":"PHASE4","title":"EVA: Evista Alendronate Comparison","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Osteoporosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"raloxifene HCI and alendronate Na","genericName":"raloxifene HCI and alendronate Na","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug uses a selective estrogen receptor modulator (raloxifene) to reduce bone resorption and a bisphosphonate (alendronate) to inhibit osteoclast-mediated bone loss, together strengthening bone density. Used for Postmenopausal osteoporosis prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}